For the time being, we are still investigating the mechanisms by which GLP-1 RA agents promote beneficial metabolic effects, out of which the following are worth mentioning: glycemic control, weight loss, adipose tissue reduction, NAFLD improvement, and benefits on inflammatory status [69]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.